Genomic-driven clinical studies in breast cancer

Genomic predictors of treatment response in prostate cancer

Synthetic lethality as a basis to select drug combinations

Genomic analysis of childhood tumours; biological and therapeutic implications

Patient-specific peptide vaccines

Proteogenomics in cancer research

Novel models to personalise cancer therapeutics

Lenalidomide with CD19 antibodies in L-MIND

Denosumab or zoledronic acid for bone disease in multiple myeloma

Extended followup indicates daratumumab with bortezomib and dexamethasone for relapsed MM

Delayed infection exposure as a trigger for childhood ALL

Triplet therapy for all comers in the CLL-BAG trial